Our portfolio

MVI is accelerating the development of malaria vaccines by testing multiple candidates simultaneously. We are strategically using our resources to support and advance a range of vaccine approaches that target both humoral and cellular immunity.

MVI portfolio

Organizations listed above

Atreca
Expres2ion
Fraunhofer CMB
Gennova
GlaxoSmithKline (GSK)

International Centre for Genetic Engineering and Biotechnology (ICGEB)
Johns Hopkins University (JHU)
Malaria Vaccine Development Program (MVDP)
Merck
National Institute of Allergy and Infectious Diseases (NIAID)
Naval Medical Research Center (NMRC)
New York University (NYU)
Seattle BioMed
University of Oxford (U Oxford)
University of Pennsylvania (UPenn)
Walter and Eliza Hall Institute (WEHI)
Walter Reed Army Institute of Research (WRAIR)

Find out more about feasibility studies, translational projects, and vaccine candidates by clicking on the respective links. Find out more about the phases of clinical trials.

View the life cycle of the malaria parasite.